CGEM

Cullinan Therapeutics INC

+$277.2M

Net Activity

Institutions Holding

174

Popularity Rank

#3228

Avg Weight

0.30%

Total Value

$934.3M

Ownership Trend

174 institutions currently hold CGEM, with 95 net buyers and 62 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

62

Net Buying Institutions

95

Key Holders

View all 174 holding institutions

Quarterly Activity

Recent Activity

+$301.2M

Total Buy Value

$143.7M

Total Sell Value

New buy34
Trim43
Add61
Sold out19

95

Net Buyers

62

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

1

Filings (90d)

$141K

Total Est. Value

8K shares

Planned Shares

Last Filed 2026-07-06
FilerFiling DateEst. Value
JENNIFER MICHAELSON2026-07-06$141K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding CULLINAN THERAPEUTICS INC (CGEM)?
Major stakeholders currently include Lynx1 Capital Management LP ($127.4M), Mpm Bioimpact LLC ($108.7M), Bvf Inc/il ($81.7M). Based on the latest 13F filings, there are a total of 174 tracked investment funds and institutions maintaining positions in CGEM.
What is the overall institutional sentiment toward CGEM recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $277.2M, driven by 95 managers accumulating shares while 62 reduced their exposure.
Which institutions have been selling or reducing their CGEM positions?
In the latest period, 43 funds trimmed their holdings, and 19 managers completely exited their positions. The aggregate reported sell value was $143.7M.
Are there any notable investors adding CGEM to their portfolios?
Yes, buying activity remains notable. 34 institutions opened new positions in {ticker}, and 61 existing holders added to their shares. The total reported buy value for the quarter amounted to $301.2M.

Related Stocks